NIFTY 50

Weakness in the rupee to benefit pharma, says IIFL

Updated : August 17, 2018 12:42 PM IST

Sanjiv Bhasin of IIFL says weakness in the domestic currency is likely to benefit pharma and not tech.

“We have a target of Rs 750 on Sun Pharma and we remain extremely bullish. We think the weakness in the rupee should ideally be played out not by IT but by pharma,” he said.

>Follow our full coverage on Indian rupee here
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV